Last reviewed · How we verify
Chemotherapy with platine
Platinum-based chemotherapy agents form DNA crosslinks that prevent cancer cell replication and induce apoptosis.
Platinum-based chemotherapy agents form DNA crosslinks that prevent cancer cell replication and induce apoptosis. Used for Lung cancer (thoracic malignancies), Various solid tumors (as part of combination chemotherapy regimens).
At a glance
| Generic name | Chemotherapy with platine |
|---|---|
| Sponsor | Intergroupe Francophone de Cancerologie Thoracique |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Platinum compounds (such as cisplatin, carboplatin, or oxaliplatin) bind to DNA and create interstrand crosslinks, disrupting DNA synthesis and repair mechanisms. This leads to cell cycle arrest and programmed cell death in rapidly dividing cancer cells. Platinum agents are non-cell-cycle-specific and are among the most effective cytotoxic chemotherapy drugs for solid tumors.
Approved indications
- Lung cancer (thoracic malignancies)
- Various solid tumors (as part of combination chemotherapy regimens)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Myelosuppression
- Nausea and vomiting
- Peripheral neuropathy
- Anemia
Key clinical trials
- Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma (PHASE2)
- Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer
- Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency
- NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (PHASE4)
- Platine, Avastin and OLAparib in 1st Line (PHASE3)
- NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: